A review published in Metabolites on August 18, 2026 compares the two drug models now available for MASH with moderate-to-advanced fibrosis: resmetirom, a thyroid hormone receptor-beta agonist, and semaglutide, a GLP-1 receptor agonist. The framing is clean: resmetirom works inside-out, semaglutide works outside-in, and together they map the metabolite networks that drive inflammation and fibrosis.
Resmetirom is liver-directed. It enhances intrahepatic lipid handling, mitochondrial fatty acid metabolism, cholesterol turnover, and lipoprotein remodeling. By easing lipotoxic stress inside the hepatocyte, it secondarily quiets inflammatory and fibrogenic signaling. The review calls this the inside-out mechanism.
Semaglutide takes the outside route. It reduces energy intake, body weight, insulin resistance, and adipose-to-liver substrate flux. Less fat arrives at the liver in the first place, so the hepatic metabolite environment improves indirectly. The review calls this outside-in metabolic unloading.
The paper walks through the metabolite networks both drugs touch: lipotoxic lipids, oxidized lipid mediators, bile acids, amino acids, acylcarnitines, redox-related metabolites, gut-derived metabolites, and extracellular matrix remodeling products. The honest caveat is that histological improvement does not by itself establish which metabolites are causal, and human mechanism data remain incomplete.
The practical idea is precision: patients dominated by intrahepatic lipotoxic stress may need the inside-out lever, while patients whose main driver is systemic metabolic overload may respond to the outside-in lever. That is a trial question today and a clinical question tomorrow.
For the reader, the review quietly restates the baseline: both drugs were studied on top of lifestyle change, and diet shapes the same metabolite environment the paper maps. The Mediterranean-style pattern with whole grains, vegetables, fish, and olive oil remains the foundation, and the drugs, when prescribed, sit on top of it.
The metabolite networks the review maps are the connective tissue between the two drugs and the plate. Lipotoxic lipids, oxidized lipid mediators, and acylcarnitines reflect how the liver handles fat. Bile acids and gut-derived metabolites connect the intestine to the liver. Amino acids and redox-related metabolites track mitochondrial function and oxidative stress. Each of these networks is shaped by diet as much as by drugs. Resmetirom improves the intrahepatic handling of these molecules, while semaglutide reduces how many of them arrive. The review explicitly notes that histological improvement does not prove which metabolites are causal, which is the honest scientific caveat behind all of it.
The complementary framing has a practical implication for how readers should hear drug news. When a headline says a drug reduced liver fat, the mechanism tells you which kind of patient it might help. A patient whose disease is driven by intrahepatic lipotoxic stress, too much fat being made inside the liver, may be the inside-out candidate. A patient whose driver is systemic metabolic overload, too much fat arriving from the body, may be the outside-in candidate. Some patients will need both. The review does not pick a winner between the drugs, and neither should a reader; the point is that the two models map the disease from two sides.
The food side of the story is where this site grounds the discussion. The same metabolite networks the paper describes are what a Mediterranean-style pattern nudges in the right direction. Vegetables and legumes support the gut-derived metabolite network through fiber. Fatty fish and olive oil shift the lipid profile. Whole grains slow glucose absorption and dampen the insulin response. Limiting added sugar and refined carbs reduces the substrate for de novo lipogenesis, which is the inside-out problem, and controlling portions reduces energy surplus, which is the outside-in problem. The plate is not a competitor to the drugs; it is the environment the drugs were studied against.
The review also quietly makes the case for monitoring. If metabolite networks are the mechanism, then measuring them, therapeutic metabolomics, could guide who gets which drug and whether it is working. That is a future clinical workflow, but it reinforces a present-day habit: regular liver enzyme checks and imaging, plus honest conversations with a clinician about weight, glucose, and lipids. The reader who tracks those numbers is already doing the monitoring that precision medicine will eventually formalize.
The precision-medicine vision in the review has a clear-eyed limit that readers should hear. Metabolite panels that guide drug choice do not exist in clinics yet, and the review says so plainly. What exists today is the older toolkit: liver enzymes, imaging, fibrosis scores, weight, glucose, and lipids. Those are the numbers a patient and clinician track now, and they are good enough to start the interventions that matter. The review’s value is directional, showing where the field is heading, not a promise that a metabolite test will arrive next year. The reader who keeps the current monitoring schedule and the Mediterranean-style plate is positioned to benefit from the precise future without waiting for it.
The reader-facing version, held to the one standard this site applies to every food, is that the two drugs pull from two sides and the plate is the shared ground. The environment the drugs were studied against is the same Mediterranean-style pattern this site rates around. That is the whole metabolomics message in one line.
The timing of the review matters as much as its content. It was published in August 2026, when both drugs are reaching real patients and the questions are shifting from whether they work to who they work best for. For a reader, the question worth asking a clinician is simple: which mechanism, the liver side or the body side, fits my profile. The answer shapes the conversation, and the plate stays the ground underneath either choice.
That is the complete reading, held to the one standard this site applies to every food: the drugs are the future levers, the plate is the present one, and the reader owns the plate.
What does inside-out versus outside-in mean?
Resmetirom works inside the liver, boosting lipid handling and mitochondrial fat oxidation through thyroid hormone receptor-beta signaling. Semaglutide works from the outside, cutting energy intake and body weight so less fat flows to the liver. The review frames them as complementary rather than competing.
Do these drugs replace diet?
No. Both were studied on top of lifestyle intervention, and the review keeps the metabolite environment, which diet shapes, at the center of the picture. The plate is the baseline; the drugs are the additional levers.
Which drug is better for fatty liver?
The review does not pick a winner. They act through different mechanisms, and the emerging idea is that some patients need the liver-directed push, others the systemic metabolic unloading, and combination strategies are an active research question.